Operations: The company generates revenue primarily through the sale and implementation of CRM systems, totaling SEK 631.84 million.

Estimated Discount To Fair Value: 15.3%

Lime Technologies, trading at SEK 365, is below its estimated fair value of SEK 431.04, suggesting a mild undervaluation. The company has demonstrated consistent financial growth with earnings increasing by 15.9% annually over the past five years and revenue projected to grow at 14.6% per year. Despite high debt levels, Lime's robust forecasted earnings growth of 24.4% annually could appeal to investors looking for cash flow-based undervalued stocks in Sweden.

• In light of our recent growth report, it seems possible that Lime Technologies' financial performance will exceed current levels.

• Delve into the full analysis health report here for a deeper understanding of Lime Technologies.

Xvivo Perfusion

Overview: Xvivo Perfusion AB is a medical technology company based in Sweden, specializing in machines and solutions for organ assessment and preservation before transplantation, operating globally with a market cap of SEK 16.06 billion.

Operations: Xvivo Perfusion generates revenue through three primary segments: Services at SEK 83.39 million, Thoracic at SEK 451.49 million, and Abdominal at SEK 163.85 million.

Estimated Discount To Fair Value: 24.4%

Xvivo Perfusion, priced at SEK 510, is observed to be significantly undervalued with a fair value estimate of SEK 674.75. Recent earnings reports show robust growth with sales reaching SEK 396.37 million in the first half of 2024, marking a substantial year-over-year increase. Expected to outpace the Swedish market, Xvivo's revenue and earnings are forecasted to grow by 24.3% and 37.83% annually respectively over the next three years. However, concerns include shareholder dilution over the past year and a highly volatile share price recently.

• Our comprehensive growth report raises the possibility that Xvivo Perfusion is poised for substantial financial growth.

• Unlock comprehensive insights into our analysis of Xvivo Perfusion stock in this financial health report.

Taking Advantage

• Explore the 47 names from our Undervalued Swedish Stocks Based On Cash Flows screener here.

• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.

• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include OM:FNOXOM:LIMEOM:XVIVO and

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com